Trial Profile

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramipril (Primary) ; Valsartan (Primary)
Indications Hypertension
Focus Pharmacodynamics
Acronyms AIM-3

Most Recent Events

18 Feb 2016 According to ClinicalTrials.gov record, the primary endpoint has been amended.
17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
10 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com